Dear {{$doctorName}},
Subject: Real World Evidence Study of Bilashine in Urticaria
Urticaria is one of the most prevalent dermatology diseases in India and has a profound effect on
quality of life and causes immense distress to the patients, necessitating effective treatment.
Various clinical studies and research have been done in last few years on the treatment
regimens, usage of anti-histamines in urticaria, in which Updosing is one of the latest &
revolutionary advancement observed across the globe.
Guideline recommends use of second generation H1 antihistamines as the first line treatment
and the dose can be increase to meet the expected results. Bilastine is classified as a non-
sedating second-generation antihistamine. It is an inverse agonist of H1 receptor which is highly
selective for only H1 receptor and has no action on other receptors. Bilastine in clinical trial was
found to be as effective as levocetirizine and safer than levocetirizine producing no sedation in
normal dosing and in Updosing.
This IPUP study has been undertaken to understand the efficacy and safety of Bilashine (Bilastine
20mg) in patients with chronic urticaria not responding to conventional dose of levocetirizine in
real life scenario.
As you will be spending some extra time to keep, copy and verify these patients records, we offer
to pay you by cheque a professional fee of Rs {{$contractAmount}}, and
accordingly on receiving the completed CRFs of number of patients that has been suggested to
you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we
hope you will consent to participate in this study. If you do, please sign and return the enclosed
reply along with your visiting card for accuracy of records.
|
}}){kind=logo}